Medical Marketing and Media - Pfizer's Neurontin ad is misleading: DDMAC
WASHINGTON INSIDER
Most Popular
3 Questions No Job Seeker Ever Wants To Be Asked?
Public Speaking: 7 Secrets Of Great Public Speakers
13 Job Interview Mistakes To Avoid
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
The Division of Drug Marketing, Advertising, and Communications (DDMAC) has ordered Pfizer Inc to discontinue use of Neurontin (gabapentin) promotional material depicting a human brain model because, DDMAC says, use of the model makes a “false” and “misleading” representation of Neurontin’s mechanism of action. The Division says that Pfizer’s model presented the human brain on one side and the other side contained headings and illustrations of cellular activity. The complaint centered around these presentations, which “suggest that the mechanism of action of Neurontin has been established in the human brain.”
Copyright CPS Communications Sep 2002
Provided by ProQuest Information and Learning Company. All rights Reserved
